Mayo Clinic and United Therapeutics Corp. can start construction on the foundation for their proposed lung-restoration center at Mayo’s Southside campus.
Imagine that Baltimore’s street lights automatically came on when they sensed someone was near, collected data about air quality and even alerted police at the sound of a gunshot.
We are feeling so #grateful! #ThankYou Cheryl C. Kagan, Hans Riemer, Carla M. Merritt, Karen McManus, Chris Van Hollen, George Leventhal, Megan Howie, @Judy Costello, @Richard Bendis, C. David Pauza, Selina Yuanyuan Milligan 樊媛媛, Virginia M Crews, Martin Rosendale, Ben Woodard, Susan Prince, Tom Hucker, Tom Wallace, Lynne Stein Benzion, CEcD, and many more for celebrating a monumental #Maryland move to 24000sqft lab+office, where we’ll launch a #HIV functional cure!
The best Data Scientists see in a slew of data what matters, communicate why it matters, and instruct others about how strategy and operations must change to address what matters.
How can Johnson & Johnson Innovation (JJI) help you reach your goals? We know what you, the innovator, need to get your science to patients. It is because of you that JJI created regional centers that host a diverse team of science and transaction experts whose goal is to find high potential early-stage innovation and, if on strategy and a fit for Johnson & Johnson, create customized deal structures to help accelerate the science to the patient.
Every marketer wants the perfect story to tell. But if you’re in medicine, you don’t want it to be about yourself.
Earlier this year, vascular surgeon John Martin was testing a pocket-sized ultrasound device developed by Butterfly Network, a startup based in Guilford, Connecticut, that he’d just joined as chief medical officer.
1ST Biotherapeutics, Inc. (1ST Bio), a private Korean biotech company, and Neuraly Inc., a startup from Johns Hopkins School of Medicine, today announced a collaboration to co-develop novel brain penetrant c-Abl inhibitors for Parkinson’s disease. Recent research has shown that inhibitors to c-Abl could slow the progression of Parkinson’s disease. Parkinson’s disease, a chronic and progressive movement disorder, is the second most common neurodegenerative disease, affecting nearly one million people in the United States.
A plan to build 12M SF of mixed-use development on a 300-acre site near the Food and Drug Administration’s HQ in Montgomery County has been in the works for nearly a decade, and the developer feels confident it can break ground in a matter of months.
Six companies presenting innovative medical device solutions that address significant unmet needs in pediatric health were awarded a total of US$250,000 in grant money in San Jose, Calif. at the Fifth Annual Pediatric Device Innovation Symposium, organized by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System.
United Therapeutics Corp (NASDAQ: UTHR), which has an office in the Research Triangle, has received approval of a new inhalation device from the U.S. Food and Drug Administration (FDA) for use with its drug Tyvaso. Tyvaso, has been the focal point of a number of patent disputes. A treatment for pulmonary hypertension (PAH), the drug generates significant sales for the company.